drugset / Trial / NCT02970292
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
Timeline
- Start
- 2016-10-26
- Primary completion
- 2019-05-28
- Completion
- 2019-06-25
Outcome
Missed primary endpoint
registry analysis (superiority test); Pimavanserin vs Placebo; p = 0.0940; Difference in MMRM LSMs -2.1 (95% CI -4.5 to 0.4) NCT02970292 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 10 mg | Oral |
| Subject | Pimavanserin | Small molecule | 20 mg | Oral |
| Subject | Pimavanserin | Small molecule | 34 mg | Oral |